MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

Junjie Xiao, Zhi Cheng Jing, Patrick T. Ellinor, Dandan Liang, Hong Zhang, Ying Liu, Xiaoli Chen, Lei Pan, Robert Lyon, Yi Liu, Lu Ying Peng, Xingqun Liang, Yunfu Sun, Laurentiu M. Popescu, Gianluigi Condorelli, Yi Han Chen

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical presentation and the lack of a reliable screening tool. MicroRNAs (miRNAs) regulate gene expression in a wide range of pathophysiologic processes. Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.Methods: Thirty-two APE patients, 32 healthy controls, and 22 non-APE patients (reported dyspnea, chest pain, or cough) were enrolled in this study. The TaqMan miRNA microarray was used to identify dysregulated miRNAs in the plasma of APE patients. The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate the dysregulated miRNAs. The receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.Results: Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P <0.001).Conclusions: Our findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE. Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to clinical utilization.

Original languageEnglish
Article number159
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - Sep 24 2011

Fingerprint

Biomarkers
MicroRNAs
Pulmonary Embolism
Plasmas
Polymerase chain reaction
Transcription
Microarrays
Medical problems
Chest Pain
Cough
Gene expression
Dyspnea
Type 2 Diabetes Mellitus
Reverse Transcription
Area Under Curve
Screening
Heart Failure
Confidence Intervals
Gene Expression
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Xiao, J., Jing, Z. C., Ellinor, P. T., Liang, D., Zhang, H., Liu, Y., ... Chen, Y. H. (2011). MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. Journal of Translational Medicine, 9(1), [159]. https://doi.org/10.1186/1479-5876-9-159

MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. / Xiao, Junjie; Jing, Zhi Cheng; Ellinor, Patrick T.; Liang, Dandan; Zhang, Hong; Liu, Ying; Chen, Xiaoli; Pan, Lei; Lyon, Robert; Liu, Yi; Peng, Lu Ying; Liang, Xingqun; Sun, Yunfu; Popescu, Laurentiu M.; Condorelli, Gianluigi; Chen, Yi Han.

In: Journal of Translational Medicine, Vol. 9, No. 1, 159, 24.09.2011.

Research output: Contribution to journalArticle

Xiao, J, Jing, ZC, Ellinor, PT, Liang, D, Zhang, H, Liu, Y, Chen, X, Pan, L, Lyon, R, Liu, Y, Peng, LY, Liang, X, Sun, Y, Popescu, LM, Condorelli, G & Chen, YH 2011, 'MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism', Journal of Translational Medicine, vol. 9, no. 1, 159. https://doi.org/10.1186/1479-5876-9-159
Xiao, Junjie ; Jing, Zhi Cheng ; Ellinor, Patrick T. ; Liang, Dandan ; Zhang, Hong ; Liu, Ying ; Chen, Xiaoli ; Pan, Lei ; Lyon, Robert ; Liu, Yi ; Peng, Lu Ying ; Liang, Xingqun ; Sun, Yunfu ; Popescu, Laurentiu M. ; Condorelli, Gianluigi ; Chen, Yi Han. / MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{4864ebe435d742a288c8944e63e71e9c,
title = "MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism",
abstract = "Background: Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical presentation and the lack of a reliable screening tool. MicroRNAs (miRNAs) regulate gene expression in a wide range of pathophysiologic processes. Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.Methods: Thirty-two APE patients, 32 healthy controls, and 22 non-APE patients (reported dyspnea, chest pain, or cough) were enrolled in this study. The TaqMan miRNA microarray was used to identify dysregulated miRNAs in the plasma of APE patients. The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate the dysregulated miRNAs. The receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.Results: Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95{\%} confidence interval, 0.737 to 0.929; P <0.001).Conclusions: Our findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE. Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to clinical utilization.",
author = "Junjie Xiao and Jing, {Zhi Cheng} and Ellinor, {Patrick T.} and Dandan Liang and Hong Zhang and Ying Liu and Xiaoli Chen and Lei Pan and Robert Lyon and Yi Liu and Peng, {Lu Ying} and Xingqun Liang and Yunfu Sun and Popescu, {Laurentiu M.} and Gianluigi Condorelli and Chen, {Yi Han}",
year = "2011",
month = "9",
day = "24",
doi = "10.1186/1479-5876-9-159",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

AU - Xiao, Junjie

AU - Jing, Zhi Cheng

AU - Ellinor, Patrick T.

AU - Liang, Dandan

AU - Zhang, Hong

AU - Liu, Ying

AU - Chen, Xiaoli

AU - Pan, Lei

AU - Lyon, Robert

AU - Liu, Yi

AU - Peng, Lu Ying

AU - Liang, Xingqun

AU - Sun, Yunfu

AU - Popescu, Laurentiu M.

AU - Condorelli, Gianluigi

AU - Chen, Yi Han

PY - 2011/9/24

Y1 - 2011/9/24

N2 - Background: Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical presentation and the lack of a reliable screening tool. MicroRNAs (miRNAs) regulate gene expression in a wide range of pathophysiologic processes. Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.Methods: Thirty-two APE patients, 32 healthy controls, and 22 non-APE patients (reported dyspnea, chest pain, or cough) were enrolled in this study. The TaqMan miRNA microarray was used to identify dysregulated miRNAs in the plasma of APE patients. The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate the dysregulated miRNAs. The receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.Results: Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P <0.001).Conclusions: Our findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE. Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to clinical utilization.

AB - Background: Acute pulmonary embolism (APE) remains a diagnostic challenge due to a variable clinical presentation and the lack of a reliable screening tool. MicroRNAs (miRNAs) regulate gene expression in a wide range of pathophysiologic processes. Circulating miRNAs are emerging biomarkers in heart failure, type 2 diabetes and other disease states; however, using plasma miRNAs as biomarkers for the diagnosis of APE is still unknown.Methods: Thirty-two APE patients, 32 healthy controls, and 22 non-APE patients (reported dyspnea, chest pain, or cough) were enrolled in this study. The TaqMan miRNA microarray was used to identify dysregulated miRNAs in the plasma of APE patients. The TaqMan-based miRNA quantitative real-time reverse transcription polymerase chain reactions were used to validate the dysregulated miRNAs. The receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the miRNA identified as the candidate biomarker.Results: Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P <0.001).Conclusions: Our findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE. Because of this finding, large-scale investigations are urgently needed to pave the way from basic research to clinical utilization.

UR - http://www.scopus.com/inward/record.url?scp=80053176268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053176268&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-159

DO - 10.1186/1479-5876-9-159

M3 - Article

C2 - 21943159

AN - SCOPUS:80053176268

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 159

ER -